endolysin

01/01/2022 - "Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus In Vitro, on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection."
10/16/2021 - "Efficacy of the Endolysin-Based Antibacterial Gel for Treatment of Anaerobic Infection Caused by Fusobacterium necrophorum."
01/01/2018 - "This may negatively impact the efficacy of the endolysin in treating some infections in vivo. "
03/25/2023 - "The results indicated that endolysin Cpl-1 can be formulated as spray dried powders suitable for inhaled delivery to the lungs for the potential treatment of pulmonary infections."
03/25/2023 - "Bacteriophage endolysin powders for inhaled delivery against pulmonary infections."

01/01/2019 - "SAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. "
10/01/2016 - "SAL200 is a new phage endolysin-based candidate drug for the treatment of staphylococcal infections. "
02/01/2013 - "To evaluate the phage endolysin SAL-1 as a therapeutic agent for Staphylococcus aureus infections, the in vitro and in vivo antibacterial properties of a pre-formulation containing recombinant SAL-1 as an active pharmaceutical ingredient were investigated. "
10/01/2018 - "Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection."
01/01/2017 - "It is a new candidate drug for the treatment of antibiotic-resistant staphylococcal infections based on a recombinant form of the phage endolysin SAL-1. "

01/01/2019 - "We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. "
01/01/2022 - "Isolation of Klebsiella pneumoniae Phage vB_KpnS_MK54 and Pathological Assessment of Endolysin in the Treatment of Pneumonia Mice Model."
10/01/2023 - "This recombinant endolysin LysSA52 exhibited lytic activity against 8 of 10 Gram-positive bacteria via agar spot-on lawn antimicrobial assay, including methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumonia, Streptococcus pyogenes, Enterococcus faecium, Enterococcus faecalis, and Bacillus atrophaeus. "

01/05/2020 - "Cpl-1, an endolysin derived from Cp-1 phage has been found to be effective in a number of in-vitro and in-vivo pneumococcal infection models. "
01/01/2015 - "Cpl-711, the most powerful endolysin against pneumococci, offers a promising therapeutic perspective for the treatment of multiresistant pneumococcal infections."

01/01/2019 - "Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model."